Curriculum vitae Malcolm Boyce Managing and Clinical Director ...

More documents

Recommendations

Info

109 Boyce MJ, Baisley KJ, Warrington SJ. Phannacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Phannacol2012; 73: 411-421. 110 Boyce M, Walther M, Nentwich H, Kirk J, Smith S, Warrington S. TOPS: an intemet based system to prevent healthy subjects from over-volunteering for clinical trials. Eur J Clin Phannacol2012; 68: 1019-1024. 111 Boyce M, David 0, Darwin K, Mitchell T, Johnson A, Warrington S. Single oral doses ofnetazepide (YF 4 7 6), a gastrin receptor antagonist, cause dose dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Phannacol Ther 2012; 36: 181-189. 112 Oliver A, Quinn D, Goldfrad C, van Hecke B, Ayer J, Boyce M. Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised clinical trial. Clin Transl Allergy 2012. [e-pub ahead ofprint] 113 Kent S, Boyce M, Diamant Z, Singh D, O'Connor B, Saggu P, Norris V. The 5-lipoxygenase activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. Clin Exp Allergy 2012. (in preparation) 114 Boyce M, Warrington S. Effect of repeated doses ofnetazepide (YF476), a gastrin receptor antagonist, compared with placebo and omeprazole on 24-hour gastric acidity and plasma gastrin in healthy subjects. (in preparation) 115 Boyce M, Warrington S, Black JW. Netazepide (YF476), an orally-active gastrin receptor antagonist, causes dose-dependent, persistent inhibition of pentagastrin stimulated gastric acid production in healthy subjects. (in preparation) 116 Boyce M, Dowen S, Warrington, Zhao C-M, Chen D, Black JW. Netazepide (YF476), an orally active gastrin antagonist, supresses gastric acid secretion and prevents the increase in ECL-cell activity and rebound hyperacidity secondary to the hypergastrinaemia induced by a proton pump inhibitor in healthy subjects. (in preparation) CVIMJB/28Jun2012 Page 18 of21
117 Webb D-L, Rudholm T, Feldreich M, Gillberg L, Halim M, Theodorsson E, Sanger G, Campbell C, Boyce M, Naslund E, Hellstrom P. The type 2 CCK2/gastrin receptor antagonist YF476 acutely prevents NSAID induced gastric ulceration: correlation with increased iNOS. (in preparation) 118 Sorda10, Waldum H, Nordrum I, Boyce, M, Bergh K, Munkvold B, Qvigstad G. The gastrin receptor antagonist YF476 prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils. (in preparation) 119 Fossmark R, Sorda10, Jianu CS, Qvigstad G, Nordrum IS, Boyce M, Waldum HL. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. (in preparation) CVIMJB/28Jun2012 Page 19 of21
Page 2 and 3: Name: Work address: Telephone: E-ma
Page 4 and 5: Senior Medical Adviser, Medical Res
Page 6 and 7: Member of the GCP Consultative Comm
Page 8: 13 Boyce MJ. Cardiovascular effects
Page 12 and 13: 52 Curtis SP, Eardley I, Boyce M, L
Page 15: 82 Andrews JM, Honeybourne D, Jevon
Page 21: to fruition many studies in patient

Curriculum vitae Malcolm Boyce Managing and Clinical Director ...

Create successful ePaper yourself

Delete template?

Save as template?